CCO Independent Conference Highlights of the 2024 San Antonio Breast Cancer Symposium *

Review a ClinicalThought commentary, summary slidesets, and a CME-certified expert analysis of key data from the 2024 San Antonio Breast Cancer Symposium (2024 SABCS).

Share

Program Content

Activities

SABCS 2024 Top Abstracts
An Expert’s Guide to SABCS 2024: A Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2024

Expires: December 05, 2025

10 Capsule Summaries

Activities

EMBER 3
EMBER-3: Imlunestrant ± Abemaciclib vs SoC ET in Patients With ER+/HER2- ABC After Progression on Prior ET
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: June 12, 2025

KEYNOTE 522 Subgroup Analyses
KEYNOTE-522: Biomarker and OS Subgroup Analyses of Neoadjuvant Pembrolizumab + CT Followed by Adjuvant Pembrolizumab in High-Risk Early TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2024

Expires: June 15, 2025

SOLTI VALENTINE
Phase II SOLTI VALENTINE: Neoadjuvant HER3-DXd ± Letrozole for High-Risk HR+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2024

Expires: June 15, 2025

PADMA
PADMA: ET + Palbociclib vs Standard Chemotherapy in High-Risk HR+/HER2- MBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2024

Expires: June 16, 2025

ELECTRA and ELEVATE
ELECTRA and ELEVATE: Elacestrant Combinations for ER+/HER2- Advanced/Metastatic Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2024

Expires: June 16, 2025

neoHIP
neoHIP: Phase II Trial of Neoadjuvant Pembrolizumab + HER2-Targeted Therapy for HER2-Positive Early Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2024

Expires: June 16, 2025

DESTINY Breast06 Subgroup Analysis
DESTINY-Breast06: T-DXd vs Chemotherapy by Pace of Progression on Previous ET in Patients With HR+/HER2-Low or HER2-Ultralow MBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2024

Expires: June 17, 2025

RIGHT Choice
RIGHT Choice: Subgroup Analyses From the Phase II Trial of First-line Ribociclib + ET vs Combination Chemotherapy in Clinically Aggressive HR+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2024

Expires: June 17, 2025

OlympiA 10 Year Follow Up
OlympiA: 10-Yr Follow-up With Adjuvant Olaparib in Patients With gBRCA1/2-Mutated HER2-Negative Early Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2024

Expires: June 17, 2025

GBG 96 GeparDouze
NSABP B-59/GBG-96-GeparDouze: Phase III Trial of Neoadjuvant CT Plus Atezolizumab Followed by Adjuvant Atezolizumab for Stage II/III TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2024

Expires: December 17, 2025

Faculty

cover img faculity

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

cover img faculity

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Commitee
Sarah Cannon Research Institute
Dallas, Texas

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.